Skip to content

Study · Randomized controlled trial · n = 1,474 · 2025

4 results

Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.

Ji L, Yuan G, Liu J, Zhang B, Liu W, Shen Z

Diabetes, obesity & metabolism22 Aug 2025Cited by 1 (Europe PMC)

PMID40843773 (opens in a new tab)PMCIDPMC12515755 (opens in a new tab)DOI10.1111/dom.70031 (opens in a new tab)PepBankPUB-40843773
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes, oral semaglutide gave greater HbA1c reductions than placebo or sitagliptin across the baseline subgroups.

    In plain wordsIn Chinese adults with type 2 diabetes, oral semaglutide lowered HbA1c more than placebo or sitagliptin in every subgroup studied.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction across baseline subgroups
    Study

    n = 1,474

    Comparator
    Placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 7 or 14 mg once daily · oral · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall, greater reductions in HbA1c and body weight were observed with oral semaglutide versus comparators across the subgroups
    3 context sentences
    Summary · context
    Changes from baseline in HbA1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA1c, body mass index, duration of diabetes, and presence of gastrointestinal disease.
    Summary · context
    Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12).
    Summary · context
    In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes, oral semaglutide gave greater body weight reductions than placebo or sitagliptin across the baseline subgroups.

    In plain wordsIn Chinese adults with type 2 diabetes, oral semaglutide led to more weight loss than placebo or sitagliptin in every subgroup studied.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction across baseline subgroups
    Study

    n = 1,474

    Comparator
    Placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 7 or 14 mg once daily · oral · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall, greater reductions in HbA1c and body weight were observed with oral semaglutide versus comparators across the subgroups
    3 context sentences
    Summary · context
    Changes from baseline in HbA1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA1c, body mass index, duration of diabetes, and presence of gastrointestinal disease.
    Summary · context
    Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12).
    Summary · context
    In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes, oral semaglutide lowered HbA1c more in subgroups with higher baseline HbA1c (significant interaction, p int <0.05).

    In plain wordsIn Chinese adults with type 2 diabetes, oral semaglutide lowered HbA1c more in people who started with higher HbA1c.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction by baseline HbA1c subgroup
    Study

    n = 1,474

    Comparator
    Placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 7 or 14 mg once daily · oral · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    A significant difference was observed for change in HbA1c by baseline HbA1c subgroups (pint 1c.
    3 context sentences
    Summary · context
    Changes from baseline in HbA1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA1c, body mass index, duration of diabetes, and presence of gastrointestinal disease.
    Summary · context
    Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12).
    Summary · context
    In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated.
  4. 04HumanRandomized controlled trialSafety outcome

    In Chinese adults with type 2 diabetes, most adverse events with oral semaglutide were gastrointestinal and mild to moderate.

    In plain wordsIn Chinese adults with type 2 diabetes, most side effects of oral semaglutide were stomach and gut related and mild to moderate.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAdverse events by baseline subgroup
    Study

    n = 1,474

    Outcome group
    Adverse events · Whole body
    Studied dose
    3, 7 or 14 mg once daily · oral · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Most AEs were gastrointestinal-related and mild-to-moderate.
    3 context sentences
    Summary · context
    Adverse events (AEs) by baseline subgroups were also assessed.
    Summary · context
    Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12).
    Summary · context
    In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.